About Verastem

Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem's portfolio of small molecule drugs inhibit critical signaling pathways in cancer including the PI3K and FAK pathways. These signaling pathways are aberrant in cancer and promote tumor survival. Preclinical research has shown that these pathways also contribute to the protective nature of the tumor microenvironment, thereby limiting the effectiveness of cancer treatments.

Verastem’s lead product candidate is duvelisib, a dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. Duvelisib has successfully met its primary endpoint in a Phase 3 registration trial for patients with relapsed/refractory Chronic Lymphocytic Leukemia (CLL), and in a Phase 2 study in refractory indolent Non-Hodgkin's Lymphoma (NHL). Verastem plans to share these clinical data with the U.S. Food and Drug Administration (FDA) with the goal of filing a New Drug Application (NDA) with the FDA during the first half of 2018.

Our lead clinical product candidate targeting focal adhesion kinase (FAK) is defactinib. Defactinib is currently being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic, ovarian and non-small cell lung cancer, and mesothelioma.